Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | CASP1 | P29466 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | CASP7 | P55210 | 2/20 | 0.50 |
| ▸ | HBB | P68871 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | PLAU | P00749 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225712 | 0.80 | CYP3A4 (0.56) | ALDH1A1CYP3A4HSD17B10CASP1HIF1A | |
| SCHEMBL145891 | 0.79 | ALDH1A1 (0.77) | ALDH1A1CYP3A4HSD17B10CASP1HIF1A | |
| SCHEMBL29367325 | 0.79 | ALDH1A1 (0.77) | ALDH1A1CYP3A4HSD17B10CASP1HIF1A | |
| SCHEMBL154872 | 0.76 | — | — | |
| SCHEMBL11718523 | 0.76 | ALDH1A1 (0.52) | ALDH1A1CYP3A4HSD17B10CASP1HIF1A | |
| Fluoride SCHEMBL27620141 | 0.76 | ALDH1A1 (0.72) | ALDH1A1CYP3A4HSD17B10CASP1HIF1A | |
| SCHEMBL2177430 | 0.75 | CYP2A6 (0.44) | ALDH1A1CYP3A4HSD17B10TDP1LMNA | |
| SCHEMBL442351 | 0.73 | ALDH1A1 (0.83) | ALDH1A1CYP3A4HSD17B10CASP1HIF1A | |
| SCHEMBL3412594 | 0.73 | ALDH1A1 (0.78) | ALDH1A1CYP3A4HSD17B10CASP1HIF1A | |
| SCHEMBL29165604 | 0.73 | ALDH1A1 (0.83) | ALDH1A1CYP3A4HSD17B10CASP1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3232193-B1 | DIAGNOSIS OF MPS I DISORDERS BY MEASURING NON-REDUCING ENDS OF GAGS AFTER ENZYMATIC DIGEST | BIOMARIN PHARM INC (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20210025874-A1 | METHODS OF DIAGNOSING A DISEASE AND METHODS OF MONITORING TREATMENT OF A DISEASE BY QUANTIFYING A NON-REDUCING END GLYCAN RESIDUAL COMPOUND AND COMPARING TO A SECOND BIOMARKER | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-01-28 | — | — | US | disclosed |
| US-20210017570-A1 | DETECTION OF OLIGOSACCHARIDES | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10793894-B2 | Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10683530-B2 | Detection of oligosaccharides | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10677786-B2 | Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20190249224-A1 | QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS FOR DETERMINING THE PRESENCE, IDENTITY, OR SEVERITY OF A DISEASE OR CONDITION | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-10260084-B2 | Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-04-16 | — | — | US | disclosed |
| EP-2900831-B1 | QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS | BIOMARIN PHARM INC (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-2376916-B1 | QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS | BIOMARIN PHARM INC (US) | 2018-10-03 | — | — | EP | disclosed |
| US-20130149729-A1 | QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS | ZACHARON PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8183003-B2 | Polymer end group detection | ZACHARON PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20120009616-A1 | DETECTION OF OLIGOSACCHARIDES | Zacharon Pharmaceuticals Inc. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2376915-A2 | DETECTION OF OLIGOSACCHARIDES | Zacharon Pharmaceuticals, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2376916-A2 | QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS | Zacharon Pharmaceuticals, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100184013-A1 | DETECTION OF OLIGOSACCHARIDES | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010078514-A2 | QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010078515-A2 | POLYMER END GROUP DETECTION | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010078511-A2 | DETECTION OF OLIGOSACCHARIDES | ZACHARON PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20070167608-A1 | Sugar chain structure profiling techniques | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017570-A1 | DETECTION OF OLIGOSACCHARIDES | MAN2B1, MAN1B1, MAN2B2 | ALDH1A1 2893/4885CYP3A4 4510/4885HSD17B10 289/4885 |
| US-10683530-B2 | Detection of oligosaccharides | MAN2B1, MAN1B1, MAN2B2 | ALDH1A1 2893/4885CYP3A4 4510/4885HSD17B10 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.